The Future of HNSCC: Aligning Teams, Transforming Care
About this episode
This episode discusses the future of head and neck squamous cell carcinoma treatment through team coordination and immune checkpoint inhibition.
CME credits: 0.25 Valid until: 02-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/The-Future-of-HNSCC-Aligning-Teams-Transforming-Care/54394/ This activity reviews data from the KEYNOTE-689 and NIVOPOSTOP trials evaluating perioperative immune checkpoint inhibition in resectable, locally advanced head and neck squamous cell carcinoma (HNSCC). Experts examine trial design, efficacy outcomes, and the role of PD-L1 combined positive score (CPS) in patient selection. Drs. Uppaluri and Lee discuss how surgical, medical, and radiation oncology teams can coordinate treatment sequencing and integrate perioperative pembrolizumab into practice for patients with locally advanced HNSCC. =
People in this episode
Host: ReachMD
Guests: Dr. Uppaluri, Dr. Lee
Topics covered
- head and neck cancer
- immune checkpoint inhibition
- perioperative care
- oncology
- treatment sequencing
Keywords
- HNSCC
- CME
- pembrolizumab
- oncology
- treatment sequencing
- KEYNOTE-689
- NIVOPOSTOP
- PD-L1
- immune checkpoint inhibition
Mentioned in this episode
Organizations: PD-L1, ReachMD, KEYNOTE-689, NIVOPOSTOP
Places: HNSCC
More episodes of ReachMD CME
- Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
- Beyond IOP: Integrating Ocular Surface Resilience Into Glaucoma Management
- Retina Rumble: Debating Modern Treatment Options
- Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
- Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
- Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
Explore listener stats, chart rankings, contacts and more on the ReachMD CME podcast page.